Moneycontrol
Aug 11, 2017 02:39 PM IST | Source: Moneycontrol.com

Claris Lifesciences: Outcome of board meeting

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2017 along with Limited Review Report for the quarter ended June 30, 2017.

Claris Lifesciences: Outcome of board meeting
The Board of Directors has considered, approved and taken on record the following:

1.Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2017 along with Limited Review Report for the quarter ended June 30, 2017.

2.Resignation of Mr. Amish Vyas from the position of Non-Executive and Non-Independent Director of the Company w.e.f. August 11, 2017.

3.Re-appointment of Mr. Arjun Handa, as Vice-Chairman and Managing Director for a period of three years w.e.f September 26, 2017, subject to approval of shareholders at general meeting.

4.Voluntary Liquidation of Claris Lifesciences De Mexico SA de CV and Claris Lifesciences Colombia Limitada.
Source : BSE
X
Sections
Follow us on
Available On